Cigna earnings beat by $0.04, revenue topped estimates
On Friday, Citi analyst Joanna Wuensch maintained a Buy rating on Abbott Laboratories (NYSE:ABT) with a steady price target of $160.00. The healthcare giant, with a market capitalization of $219 billion, maintains a "GREAT" financial health score according to InvestingPro analysis, demonstrating strong operational efficiency and market leadership in the Healthcare Equipment & Supplies industry. Wuensch’s evaluation followed a recent legal development where a judge overturned a previous verdict from October 31, 2024, which had favored Reckitt Benckiser (LON:RKT)’s Mead Johnson unit in the Whitfield infant formula case. The initial jury decision had absolved Mead Johnson of the responsibility to warn about the risks of Necrotizing Enterocolitis (NEC) associated with its infant formula products.
The overturned verdict is seen as a potentially negative factor for Abbott, as the company faces its own Federal multi-district litigation (MDL) case, set to begin on May 5, 2025, in Chicago. The proceedings are expected to last four weeks, followed by an eight-week pause, with the potential for 3-4 cases to be processed throughout the year. Although state cases and the MDL operate independently, the recent turn of events in the state case could impact the market’s perception of Abbott’s ongoing legal challenges.
Abbott’s stock had previously seen an approximate 15% increase year-to-date, partly due to easing concerns around NEC litigation. This performance aligns with InvestingPro data showing the company’s strong dividend history, having maintained payments for 55 consecutive years with a current yield of 1.82%. Wuensch’s commentary suggests that while the Buy rating remains unchanged, there is a cautious stance regarding the stock’s near-term prospects in light of the legal developments. InvestingPro subscribers have access to 10+ additional exclusive insights about Abbott’s financial health and market position.
Investors have been closely monitoring the situation, as legal outcomes can significantly influence the market performance of companies involved in high-profile cases. Abbott Laboratories, a leading player in the healthcare sector with a P/E ratio of 16.5 and strong analyst support, is now under renewed scrutiny as it prepares for its upcoming legal battles. For comprehensive analysis of Abbott’s financial position and future prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which provides in-depth insights into the company’s valuation and growth potential.
In other recent news, Abbott Laboratories has been involved in several notable developments. The company is facing a retrial in the Whitfield case, which concerns allegations linking its infant formula to necrotizing enterocolitis in premature infants. This legal challenge has introduced uncertainty for Abbott, as the appeals process could extend over the next two years. Meanwhile, Abbott has entered into a collaboration with Cadrenal Therapeutics for a pivotal clinical trial aimed at improving treatment for patients with left ventricular assist devices. This partnership leverages Abbott’s expertise in mechanical circulatory support devices.
Additionally, defensive stocks, including Abbott, have recently gained traction amid market shifts away from tech stocks due to concerns over China’s DeepSeek AI model. In terms of stock analysis, Barclays (LON:BARC) recently raised its price target for Abbott Labs to $158, maintaining an Overweight rating, in light of management’s updated financial outlook. Despite facing foreign exchange and tax rate headwinds, Abbott has raised its gross margin expectations and set a 2025 earnings per share growth guidance.
Furthermore, Bernstein increased its price target for Abbott to $138, maintaining an Outperform rating, citing strong performance in the company’s Medical (TASE:BLWV) Devices segment. Abbott’s organic growth, particularly in Continuous Glucose Monitoring and Structural Heart products, has been highlighted as a key factor in its positive outlook. These developments reflect Abbott’s ongoing efforts to navigate legal challenges, foster strategic collaborations, and capitalize on growth opportunities in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.